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Background: Ferritin even though widely recognized as a representative of total body iron stores, its prognostic
utility is linked with COVID-19. This study was aimed at evaluation of the association of ferritin with severity in
Coronavirus disease 2019 (COVID-19), hospitalized patients and to test the hypothesis that it is an independent
predictor of mortality.
Material and methods: This study was conducted at Chemical Pathology, Department of Pathology and Laboratory
Medicine, Aga Khan University (AKU), Karachi. Medical records of all in-patients including both genders, and all
age groups with documented COVID-19 from 1st March to 10th August 2020 were reviewed. The subjects were
divided into two categories severe and non-severe COVID-19; and survivors and non-survivors. The details were
recorded on a pre-structured performa. Between-group differences were tested using the Mann–Whitney’s U-test.
The receiver operating characteristic curve was plotted for ferritin with severity and mortality. A binary logistic
regression was used to identify variables independently associated with mortality. The data was analyzed using
Statistical Package for the Social Sciences (SPSS).
Results: A total of 336 in patients were reviewed as declared COVID-19 positive during the study duration, and
157 were included in the final analysis including 108 males and 49 females. Statistically significant difference in
ferritin was found in the two categories based on severity and mortality. Binary logistic regression showed
ferritin to be an independent predictor of all-cause mortality supplemented with an AUC of 0.69 on ROC analysis.
Conclusions: Serum ferritin concentration is a promising predictor of mortality in COVID-19 cases.

1. Introduction
The novel coronavirus disease 2019 (COVID-19) that emerged in
December 2019 in Wuhan (Hubei, China), has surprisingly occupied the
entire globe overwhelmingly, with many countries experiencing the
second wave [1]. Even though the rapidly evolving clinical course and
presentation continue to amaze the medical fraternity, cases infected
with this severe acute respiratory syndrome coronavirus 2 (SAR
S-CoV-2), often present with severe pneumonia and organ targeted in
juries involving the liver, heart, and kidneys [2].
With the surging devastating effects of the pandemic, the focus of
scientific efforts was on developing optimal therapeutic regimens to
combat the virus. Meanwhile, there was also a dire need for early risk

stratification systems and biomarkers to predict disease progression, to
identify high-risk patients at an early stage of the infection [3–5]. This
can optimize management goals, and overcome the shortage of medical
and material resources which was particularly evident amidst this global
emergency.
The primary triggering event, associated with severity and mortality
has been the inflammatory cytokine storm, characterized by abrupt and
excess release of pro-inflammatory cytokines including inflammatory
cytokines released by macrophages particularly the interleukins IL-6, IL10, and tumor necrosis factor (TNF-α) [6]. With this pivotal event of the
pathophysiological mechanism in perspective, biochemical analysis of
plasma inflammatory markers and positive acute phase reactants
including ferritin could be useful for predicting the disease progression

* Corresponding author. Chemical Pathology, Department of Pathology and Laboratory Medicine, The Aga Khan University, Pakistan.
E-mail addresses: sibtain.ahmed@aku.edu (S. Ahmed), zeeshan.ansar@aku.edu (Z. Ansar Ahmed), imran.siddiqui@aku.edu (I. Siddiqui), naveed.rashid@aku.edu
(N. Haroon Rashid), maheenmansoor2009@hotmail.com (M. Mansoor), lena.jafri@aku.edu (L. Jafri).
https://doi.org/10.1016/j.amsu.2021.02.009
Received 25 January 2021; Received in revised form 31 January 2021; Accepted 2 February 2021
Available online 12 February 2021
2049-0801/© 2021 Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd.
This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).

S. Ahmed et al.

Annals of Medicine and Surgery 63 (2021) 102163

The data was analyzed using Statistical Package for the Social Sci
ences (SPSS) version 26 (IBM Corp., Armonk, NY). As the data that was
skewed; median values were reported along with interquartile ranges
(IQR) for continuous variables. Between-group median differences were
tested using the Mann–Whitney’s U-test for continuous. P < 0.05 was
considered statistically significant and P < 0.01 as highly significant.
The receiver operating characteristic curve (ROC) was plotted to further
appraise the relationship of ferritin with severity and mortality respec
tively and the area under the curve (AUC) calculated. The cut-off values
were determined as the maximum value giving the best balance between
sensitivity and specificity. Moreover, a binary logistic regression was
also used to evaluate the association with mortality.

[7]. Ferritin occurs as a cytosolic protein in most tissues, although a
mitochondrial form also exists and nuclear localization has been pro
posed [8]. Even though widely recognized as a representative of total
body iron stores, its prognostic utility is linked with acute and chronic
inflammatory processes and is nonspecifically raised in a variety of such
disorders, including chronic kidney disease, rheumatoid arthritis, and
autoimmune disorders, etc. [9].
In one study from China with twenty COVID-19 cases, it was found
that individuals with severe diseases often present with increased serum
ferritin levels, with a statistically significant difference between severe
and mild categories [10]. Whereas another study conducted using re
cords from a large multi-hospital New York City health system demon
strated poor performance of serum ferritin for the prediction of
mortality [11].
Owing to the scarcity of literature on the role of ferritin, and the
contrasting results demonstrated by various studies on the potential
association with severity and mortality in context, this study was aimed
at evaluation of the association of the biomarker with severity in a
cohort of hospitalized cases with COVID-19 at a tertiary care referral
center in Karachi, the metropolis hardest hit by the pandemic in
Pakistan.

3. Results
A total of 336 inpatients were reviewed as declared COVID-19 pos
itive during the study duration. Ninety-seven cases i.e. 29% were
excluded in the data collection phase as they opted out from their
treatment at AKU after a positive COVID-19. The study sample was
further scrutinized based on the exclusion criteria and a total of 157
cases were included in the final analysis as shown in Fig. 1. There were a
total of 86 (55%) cases in the severe category and out of these 28 (33%)
progressed to mortality. Whereas, 71 (45%) of the non-severe category
survived.
The demographic details, length of hospital stay, and serum ferritin
levels in the severe and non-severe groups and survivor and nonsurvivor groups respectively are depicted in Table 1 and Table 2. Me
dian ferritin being 828.5(IQR: 428.5–1386.7) and 357.5(IQR:
198.91098) ng/mL was found to be significantly higher in the severe
group compared to the non-severe cases group respectively (p value =
0.005) however the association with severity was lost on binary logistic
regression analysis (p value = 0.082). Whereas, the ferritin levels with a
median value of 1096.4 ng/mL in the non-survivor group, were found to
be significantly higher compared to survivors (p-value = 0.02) and was
found to be an independent predictor of mortality on binary logistic
regression (p-value = 0.02). Furthermore, older age and increased
duration of hospital stay were also revealed as variables independently
associated both with severity and mortality as shown in Tables 1 and 2.
ROC curve analysis was used to compare the performance of ferritin
as a predictor of mortality and severity. Ferritin was a slightly better
predictor of mortality than severity, with an AUC of 0.69 (95% CI:
0.58–0.79) and 0.66 (95% CI: 0.57–0.74) respectively as illustrated in
Fig. 2. The optimal cut-off for prediction of mortality was 574.5 ng/mL
with a sensitivity of 82% at the cost of specificity i.e. 51%. Whereas, for
the prediction of severity the optimal cut-off identified was 354 ng/mL
with a sensitivity of 80% at a compromised specificity i.e. 50%. The
study sample was further categorized into three categories based on
serum ferritin levels <500, >500, and >1000 ng/mL, and the case dis
tribution according to severity and mortality was assessed as shown in
Fig. 3. In the third category of >1000 ng/mL most of the severe cases (n
= 39, 40%) and the majority of the expired cases (n = 14, 50%) were
placed.

2. Material and Methods
This retrospective observational study was conducted at the section
of chemical pathology, department of Pathology and Laboratory Medi
cine, in collaboration with the section of molecular pathology and
intensive care unit, department of Internal Medicine, Aga Khan Uni
versity (AKU), Karachi, Pakistan. The hospital was the first to launch
treatment facilities for COVID-19 in Pakistan. Being accredited by the
Joint Commission International (JCI), the hospital serves a population
from across the country. The hospital houses the leading infectious
disease consultants of the country alongside dedicated areas for COVID19 screening and treatment with optimal infection control practices. The
study was approved by the institutional ethical review committee of the
AKU, Karachi (ERC#2020-5168-14099). Our study was registered with
Chinese Clinical Trial Registry (Registration No: ChiCTR2100042375).
This work has been reported in line with the STROCSS criteria [12].
Medical records of all in-patients including both genders and all age
groups with SARS-CoV-2 positive on a reverse-transcriptase polymerase
chain reaction (PCR) test from 1st March to 10th August 2020 were
reviewed. The PCR specimen was collected on a nasopharyngeal swab
using Cobas® SARS-CoV-2 Qualitative assay for use on the Cobas®
6800/8800 Systems (Roche Molecular Systems).
The demographic details, length of stay in the hospital, and outcome
(survived or expired) at the time of discharge along with the results of
ferritin levels were recorded on a pre-structured questionnaire. Of all the
COVID-19-positive patients, only hospitalized patients aged 18 years
and older with a ferritin level available over admission were included in
the analysis. Owing to the limitations of retrospective data analysis,
ferritin levels obtained within 48 h of admission were acquired. If
multiple ferritin levels were obtained, then the one closest to admission
was recorded. Serum ferritin was measured by Chemiluminescence
immunoassay (CLIA) on the Siemens Advia Centaur immunoassay
analyzer using the manufacturer’s recommendations. Results are
expressed as nanogram of ferritin per microliter of serum (ng/mL). For
internal quality control, 2 levels of manufacturer-provided controls (low
and high) were run with each batch of analyte while the laboratory is
accredited by the College of American Pathologists (CAP), ensuring
optimal external quality assurance.
For assessing the role of ferritin in mortality prediction, the study
sample was further divided into two groups i.e. survivors and nonsurvivors. Likewise, two groups were formulated to assess’ severity,
being defined as having either of the two criteria; requiring intensive
care admission or assisted respiration based on invasive ventilation or
non-invasive oxygen support.

4. Discussion
During the global COVID-19 pandemic, the role of laboratory med
icine for aid in clinical decision making was mainly focused on prompt
risk stratification for smart resource allocation in already exhausted as
well as resource-constrained setups in the case of low middle-income
countries (LMIC) like Pakistan. Of the various biomarkers evaluated
by clinicians based on prior experience of viral pathogens majority were
pro-inflammatory cytokines including IL-6, Procalcitonin, lactate de
hydrogenase, and C-reactive protein. However, from a laboratorian’s
perspective, the majority of the small lab set up particularly in LMIC
does not have most of these biomarkers readily available on their testing
menu. Whereas, ferritin being a commonly used biomarker in
2
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Fig. 1. Flow diagram of data scrutiny of cases.
Table 1
Case details and ferritin in Severe Vs Non-Severe group.

Age in years (Median IQR)
Length of hospital stay in days (Median IQR)
Ferritin in ng/mL (Median IQR)

Severe Cases (n = 86)
M:F (60:26)

Non-Severe Cases (n = 71)
M:F (48:23)

Mann–Whitney’s U-test (p-value)

Binary logistic regression (p-value)

59.5 (52–70)
13 (8–20)
828.5 (428.5–1386.7)

54 (39–68)
8 (4–12)
357.5 (198.91098)

0.528
0.001
0.005

0.01
0.002
0.082

P < 0.05 statistically significant and P < 0.01 highly significant.
Table 2
Case details and ferritin in Survivor Vs Non-Survivor group.

Age in years (Median IQR)
Length of hospital stay in days (Median
IQR)
Ferritin in ng/mL (Median IQR)

Survivor Cases (n = 129)
M:F (87:42)

Non-Survivor Cases (n = 28)
M:F (21:07)

Mann–Whitney’s U-test (pvalue)

Binary logistic regression (pvalue)

56 (44.5–66)
9 (6–14)

65.5 (57.25–76.25)
17 (5–25.75)

0.008
0.022

0.0001
0.012

548.9 (248.1–1137.9)

1096.4 (609.75–1614.5)

0.02

0.024

P < 0.05 statistically significant and P < 0.01 highly significant.

hematologic disorders is widely available and it is relatively inexpen
sive. The logistics, availability, and financial benefits pose ferritin as a
potential tool for COVID-19 risk stratification.
This retrospective analysis of 157 COVID-19 patients admitted to a
large tertiary referral center, shows that ferritin levels, either obtained at
presentation or near to admission, are a relatively nonspecific test in
predicting the evaluated outcomes, namely all-cause mortality, and
severity. This was shown via several analytic techniques, including ROC
analysis obtained at optimal cutoff ferritins. There seemed to be some
moderate predictive power in ferritin being able to discriminate allcause mortality with an AUC of 0.69 and a significant association on
binary logistic regression. Likewise, Bennouar S et al. have also reported

an AUC of 0.63 for severity in prediction in a cohort of 330 Algerian
patients with COVID-19 in the period between the 27th of March and
22nd of April 2020 [13]. Another study by Jonathan et al., based on a
retrospective review of 942 adult COVID-19 cases from New York city
health system database, have also reported almost similar AUC for
mortality and severity in COVID-19, being 0.63 and 0.68 respectively
[14].
Pastora J et al. in a systematic review on the utility of ferritin in
COVID-19 has revealed that ferritin concentrations of COVID-19 pa
tients were generally within the normal range of less than 400 ng/ml in
patients with the non-severe disease [7]. However, hyperferritinemia
(ferritin level > 400 μg/L), was observed in patients with a severe
3
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Fig. 2. ROC analysis for ferritin against severity and mortality.

Fig. 3. Distribution of cases (n) with hyperferritinemia in the four study groups.

disease on admission, precisely between 1.5 and 5.3 times higher in
patients. In conjunction, our study also exhibited significantly higher
results in the severe category of cases. Pastora J et al. also evaluated
studies comparing ferritin levels on admission between COVID-19 pa
tients between survivors and non-survivors and demonstrated that
non-survivors showed ferritin levels on admission around 1400 ng/mL,
which is between 3 and 4 times higher than that observed in survivors.
Likewise, our findings with a median ferritin of 1096.4 (IQR:
609.75–1614.5) ng/mL in the all-cause mortality group was coherent
with similar studies reported from China.
Our study reported a male predominance with COVID-19 (n = 108,
69%). Likewise, a retrospective cohort study of 239 hospitalized COVID19 cases from Lombardy, Italy reported 71% of cases being males and
another report from Wuhan China reported 75% [15,16]. Furthermore,
the increasing of the patients was an independent predictor of mortality
as well as a significant association was noted with severity, with the
median age being 65.5 years and 56 years in the non-survivors and se
vere category. Results reported by Luo Xiaomin et al. in 298 COVID-19

cases from China spanning from 30 January to 20 February 2020 s our
findings, where a high proportion of mortality was noted for the age
group above 60 years and increasing age was linked with disease
advancement [17]. In cohesion with our findings, the global literature
has also demonstrated a high association of mortality with older age and
mortality in COVID-19 [18,19].
The strengths of this study encompass the large patient population
from a COVID hit metropolis, with an optimal number of patients
achieving our outcomes of interest and power of the study within a
relatively short span of time. Our study certain limitations, mostly owing
to its retrospective nature. Less than half of the patients in our original
data set had a ferritin value recorded, the missing set if included could
potentially affect our findings. This study only evaluated ferritins drawn
within 2 days of presentation, we did not explore the impact of serial
ferritins over time and how changes in ferritin values could predict
outcomes. Moreover, pre-COVID-19 ferritin levels were only available
for one patient who was a known thalassemia case and was excluded.
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5. Conclusion

Declaration of competing interest

On admission ferritin concentration is a promising predictor of
mortality, though, it cannot reliably predict severity. However, owing to
statistically significant results obtained and its widespread availability,
it is a useful marker of risk scarification in COVID-19 and can be
considered in combination with clinical details and other laboratory
tests while designing the patient centered treatment plans.
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